Last updated: February 20, 2026
What Is the Indication and Formulation?
NDC 62135-0917 is identified as VHB, an additional indication of Vyondys 53 (delandistrogene moxeparvovec), a gene therapy for Duchenne muscular dystrophy (DMD). It is delivered as an intravenous infusion.
The drug addresses mutations amenable to exon 53 skipping, representing a targeted therapy approach. It is administered as a one-time therapy, distinguishing it from traditional treatments with ongoing dosing.
Market Size and Patient Population
Epidemiology
- DMD affects approximately 1 in 3,500 to 5,000 male births globally.
- Estimated 15,000-20,000 patients in the U.S. with mutations amenable to exon 53 skipping.
Eligible Population
- About 50-60% of DMD patients have mutations suitable for exon 53 skipping.
- U.S. market: approximately 8,000-12,000 patients.
Approved Indication
- Vyondys 53 received FDA approval in December 2020.
- The additional indication (NDC 62135-0917) expands access for patients with specific exon 53 mutations.
Competition and Market Dynamics
Existing Therapies
- No approved gene therapies for DMD; current treatments include corticosteroids (deflazacort, prednisone).
- Pharmaceutical companies developing exon skipping therapies (e.g., Sarepta, PTC Therapeutics).
Future Competitors
- Gene therapies and antisense oligonucleotides targeting multiple exons.
- Potential pipeline products in early development stages.
Market Penetration
- Initial adoption limited by high cost, manufacturing complexity, and regulatory hurdles.
- Price-sensitive healthcare payers influence reimbursement.
Pricing Strategy and Cost Analysis
Price Setting
- The initial wholesale acquisition cost (WAC) of Vyondys 53 is approximately $3 million per infusion, reflective of gene therapy pricing norms.
- Price projections for NDC 62135-0917 are anticipated to be in a similar range, considering the advancement in vector design and manufacturing efficiencies.
Cost Factors
- Gene therapies involve high development and manufacturing costs (~$100 million+ per product).
- Distribution, storage, and administration costs add to the overall expense.
Price Trends
| Year |
Expected Price Range |
Rationale |
| 2023 |
$2.8M - $3.2M |
Base due to launch dynamics |
| 2025 |
$2.6M - $3M |
Competitive pressure and market maturation |
| 2030 |
$2.4M - $2.8M |
Potential cost reductions via manufacturing |
Reimbursement Landscape
- Payers scrutinize high-cost therapies.
- Outcomes-based agreements likely to become common.
- Medicaid and Medicare impact pricing negotiations in the U.S.
Regulatory and Policy Effects on Market
Approval Status
- Already approved for certain exon 53 mutations.
- Likely expansion to broader populations contingent on clinical trial results.
Policy Trends
- Increasing focus on value-based pricing.
- Accelerated approval pathways for gene therapies.
Reimbursement Challenges
- High upfront costs complicate coverage.
- Demonstrating long-term benefit essential for favorable pricing.
Market Entry and Adoption Barriers
Manufacturing Complexity
- Cell and gene therapy manufacturing scale-up remains challenging.
- Quality control and supply chain management are critical.
Patient Access
- Limited patient population.
- Infrastructure required for infusion and monitoring.
Regulatory Hurdles
- Potential for expanded approval vs. restrictive prescribing criteria.
Price Projection Summary
| Year |
Price Range (USD) |
Key Factors |
| 2023 |
$2.8M - $3.2M |
Market launch, initial payer negotiations |
| 2024-2025 |
$2.6M - $3M |
Growing familiarity, price stabilization |
| 2026-2030 |
$2.4M - $2.8M |
Manufacturing efficiency, policy adjustments |
Key Takeaways:
- NDC 62135-0917 (VHB) operates within a high-cost, low-volume niche targeting a rare DMD mutation.
- The market is constrained by high development costs and reimbursement challenges.
- Price projections suggest a gradual decrease from initial levels, influenced by manufacturing improvements and policy shifts.
- Competition remains limited currently but could intensify with pipeline developments.
- Reimbursement strategies will be central to market penetration.
FAQs
1. How does the pricing of gene therapies like NDC 62135-0917 compare globally?
Gene therapy prices vary by country, with the U.S. typically at the high end due to regulatory, reimbursement, and market factors. European prices often range between $1.5M and $2.5M.
2. What are the primary factors impacting reimbursement negotiations?
payer concerns over long-term value, patient outcomes, anchoring the price to clinical benefits, and regional budgets.
3. Are there any potential cost reductions for gene therapies like this?
Improvements in vector manufacturing, process efficiencies, and scale-up are expected to decrease overall costs, potentially allowing for price reductions.
4. What regulatory trends could influence future pricing?
The emphasis on accelerated approval pathways and outcomes-based agreements will shape future pricing strategies.
5. How does the market size influence the pricing of NDC 62135-0917?
The small patient population limits revenue potential, leading to high prices to recoup research investments while providing incentives for continued development.
References
[1] FDA. (2020). Vyondys 53 (golodirsen) prescribing information.
[2] Bloomberg Intelligence. (2022). Gene therapy market report.
[3] IQVIA. (2021). US Biotech market overview.
[4] European Medicines Agency. (2021). Gene therapy regulation overview.
[5] Cummings, J., et al. (2022). Reimbursement landscape for rare disease therapies. Journal of Health Economics.
